Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease

Journal of Neural Transmission, Supplement

Volumn , Issue 55, 1999, Pages 71-77

  Piallat, B ^a   Benazzouz, A ^a   Benabid, A L ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; GLUTAMIC ACID; KAINIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; NERVE CELL DEGENERATION; NERVE PROJECTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; IMMUNOHISTOCHEMISTRY; NERVE CELL; PHYSIOLOGY; REVIEW; THALAMUS NUCLEUS;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; IMMUNOHISTOCHEMISTRY; NEURONS; PARKINSON DISEASE, SECONDARY; RATS; THALAMIC NUCLEI;

EID: 0032589188     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-6369-6_7     Document Type: Article

References (21)

1. Aziz TZ, Peggs D, Sambrook MA, Crossman AR (1991) Lesion of the subthalamic nucleus for the alleviation of protection protection protection 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 6: 288-292
2. Benazzouz A, Gross C, Féger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement ín motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5: 382-389
3. Benazzouz A, Piallat B, Pollak P, Benabid AL (1995) Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. Neurosci Lett 189: 77-80
4. Benazzouz A, Boraud Th, Féger J, Burbaud P, Bioulac B, Gross Ch (1996) Alleviation of experimental hcmiparkinsonism by high frequency stimulation of the subthalamic nucleus in primate: A comparison with L-dopa treatment. Mov Disord 11: 627-632
5. Bergman H, Wichmann T, Delong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249: 1436-1438
6. Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72: 507-520
7. Hammond C, Deniau JM, Rizk A, Féger J (1978) Electrophysiological demonstration of an excitatory subthalamonigral pathway in the rat. Brain Res 151: 235-244
8. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Lebas JF, Broussole E, Perret JE, Benabid AL (1995a) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. The Lancet 345: 91-95
9. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Broussolle JE, Perret J, Benabid AL (1995b) Bilateral subthalamic nucleus stimulation for severe Parkinson's disease. Mov Disord 10: 672-674
10. Marshall JF, O'Dell SJ, Weihmuller FB (1993) Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. J Neural Transm 91: 241-254
11. Miller WC, De Long MR (1987) Altered Ionic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayaraman A (eds). The basal ganglia II, Advances in Behavioral Biology 32 Plenum, New York pp 415-427
12. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR (1989) Neural mechanisms underlying parkinsonian symptoms base upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci 32: 213-226
13. O'Dell SJ, Weihmuller FB, Marshall JF (1992) MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow in neurotoxins and neurodegenerative disease. Ann NY Acad Sci 648: 317-319
14. Parent A, Hazrati L (1995) Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev 20: 128-154
15. Piallat B, Benazzouz A, Benabid AL (1996) Subthalamic nucleus lesion in rat prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioral and immunohistochemical studies. Eur J Neurosci 8: 1408-1414
16. Robledo P, Féger J (1990) Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res 518: 47-54
17. Sonsalla PK, Nicklas WJ, Heikkila RE (1989) Role for excitatory amino acids in methamphetamine induced nigrostriatal dopaminergic toxicity. Science 243: 398-400
18. Sonsalla PK, Riordan DE, Heikkila RE (1991) Competitive and non competitive antagonists at NMDA receptors protect against methamphetamine-induced dopaminergic damage in mice. J Pharmacol Exp Ther 256: 506-512
19. + produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 58: 1975-1978
20. + neurotoxicity by NMDA antagonists. Nature 349: 414-418
21. Zuddas A, Oberto G, Vaglini F, Fascetti F, Fornai F, Corsini GU (1992) MK-801 prevents MPTP-induced parkinsonism in primates. J Neurochem 59: 133-739